Idenix Pharmaceuticals Sets New 12-Month High at $24.22 (IDIX)
Idenix Pharmaceuticals (NASDAQ:IDIX) hit a new 52-week high on Tuesday , Stock Ratings News reports. The company traded as high as $24.22 and last traded at $24.17, with a volume of 1,137,907 shares trading hands. The stock had previously closed at $24.10.
A number of research firms have recently commented on IDIX. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Idenix Pharmaceuticals in a research note on Tuesday, June 10th. They now have a $5.00 price target on the stock, down previously from $24.50. Separately, analysts at JMP Securities upgraded shares of Idenix Pharmaceuticals to a “market perform” rating in a research note on Monday, June 9th. Finally, analysts at Robert W. Baird upgraded shares of Idenix Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Monday, June 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.00.
The stock has a 50-day moving average of $14.37 and a 200-day moving average of $8.45. The company’s market cap is $3.646 billion. Idenix Pharmaceuticals also was the recipient of a large drop in short interest in June. As of June 13th, there was short interest totalling 16,866,953 shares, a drop of 15.9% from the May 30th total of 20,048,562 shares. Approximately 14.4% of the shares of the stock are sold short. Based on an average daily volume of 7,558,808 shares, the short-interest ratio is currently 2.2 days.
Idenix Pharmaceuticals (NASDAQ:IDIX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.24) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.19) by $0.05. Analysts expect that Idenix Pharmaceuticals will post $-0.88 EPS for the current fiscal year.
Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.